35
Participants
Start Date
October 23, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
BGB-A445
Administered intravenously at protocol defined dose
Docetaxel
75 milligrams per square meter (mg/m\^2) administered intravenously
Ramucirumab
10 mg/kg administered intravenously
BGB-15025
Administered orally at protocol defined dose
National Cancer Center, Goyang-si
The Catholic University of Korea, St Vincents Hospital, Suwon
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Affiliated Hospital of Jiangnan University South Campus, Wuxi
Weihai Municipal Hospital, Weihai
The Second Affiliated Hospital of Shandong First Medical University, Taian
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
Daping Hospital, Third Military Medical University, Chongqing
The Second Xiangya Hospital of Central South University, Changsha
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou
West China Hospital, Sichuan University, Chengdu
Gansu Provincial Hospital, Lanzhou
Shanxi Provincial Cancer Hospital, Taiyuan
Severance Hospital Yonsei University Health System, Seoul
Lead Sponsor
BeiGene
INDUSTRY